This inventor holds 1 USPTO granted patent. Top assignee: Nagoya University. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: Hisaaki Ishiguro: Innovator in Nitric Oxide Synthase Activation
Introduction
Hisaaki Ishiguro is a prominent inventor based in Aichi, Japan. He has made significant contributions to the field of biomedical research, particularly in the activation of endothelial nitric oxide synthase. His work focuses on developing methods to enhance vasodilation, which is crucial for cardiovascular health.
Latest Patents
Hisaaki Ishiguro holds a patent titled "Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation." The objective of this patent is to identify a nitric oxide synthase activator, establish a method for its administration, and determine the appropriate dosage. The patent discloses a nitric oxide synthase activator that comprises a midkine family protein or a midkine derivative as an active ingredient. Specifically, it details a method of administration through the blood, a coronary artery, or a vein.
Career Highlights
Hisaaki Ishiguro is affiliated with Nagoya University, where he conducts his research and development activities. His innovative work has garnered attention in the scientific community, contributing to advancements in medical treatments related to cardiovascular health.
Collaborations
Hisaaki Ishiguro has collaborated with notable colleagues, including Arihiro Sumida and Itsuo Kodama. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Hisaaki Ishiguro's contributions to the field of nitric oxide synthase activation represent a significant advancement in biomedical research. His innovative approach and collaboration with esteemed colleagues continue to pave the way for future developments in cardiovascular therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
